Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Deffered Revenue (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Non-Current Deffered Revenue for 13 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue rose 110.19% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, up 110.19% year-over-year, with the annual reading at $5.5 million for FY2025, 110.19% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $5.5 million at Niagen Bioscience, up from $2.7 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $5.5 million in Q4 2025, with the low at $2.6 million in Q3 2024.
  • Average Non-Current Deffered Revenue over 5 years is $3.7 million, with a median of $3.8 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue tumbled 32.24% in 2024, then skyrocketed 110.19% in 2025.
  • Over 5 years, Non-Current Deffered Revenue stood at $4.3 million in 2021, then decreased by 6.98% to $4.0 million in 2022, then fell by 17.22% to $3.3 million in 2023, then decreased by 21.47% to $2.6 million in 2024, then surged by 110.19% to $5.5 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $5.5 million, $2.7 million, and $2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.